A study with three years of follow-up shows that the drug stays effective and safe for most, although 16% stopped getting treated with Dupixent, mainly because it was ineffective or caused side effects.
|Articles|July 1, 2001
Sex, drugs and your employees: Targeting the other STD
Forget the taboo. Sexually transmitted diseases are costing American employers just as much as more socially acceptable medical conditions. A panel of experts from the public and private sectors suggests actions.
Advertisement
Advertisement
Related to this article
Elevated levels of immunoglobulin G (IgG) drive “inflammaging” processes that take a toll on skin tissue as people age, according to research results reported by Japanese researchers. Reducing IgG may mitigate the loss of collagen and elastin.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Heather Burrell Ward, M.D., on personalizing TMS in schizophrenia
2
Why consumers still can’t comparison shop for medication
3
Teledentistry is a step in closing the gap in dental care
4
FDA approves Lilly’s Onswik, the second once-weekly insulin
5